Literature DB >> 20648613

Early and reliable detection of herpes simplex virus type 1 and varicella zoster virus DNAs in oral fluid of patients with idiopathic peripheral facial nerve palsy: Decision support regarding antiviral treatment?

Andreas Lackner1, Harald H Kessler, Christian Walch, Stefan Quasthoff, Reinhard B Raggam.   

Abstract

Idiopathic peripheral facial nerve palsy has been associated with the reactivation of herpes simplex virus type 1 (HSV-1) or varicella zoster virus (VZV). In recent studies, detection rates were found to vary strongly which may be caused by the use of different oral fluid collection devices in combination with molecular assays lacking standardization. In this single-center pilot study, liquid phase-based and absorption-based oral fluid collection was compared. Samples were collected with both systems from 10 patients with acute idiopathic peripheral facial nerve palsy, 10 with herpes labialis or with Ramsay Hunt syndrome, and 10 healthy controls. Commercially available IVD/CE-labeled molecular assays based on fully automated DNA extraction and real-time PCR were employed. With the liquid phase-based oral fluid collection system, three patients with idiopathic peripheral facial nerve palsy tested positive for HSV-1 DNA and another two tested positive for VZV DNA. All patients with herpes labialis tested positive for HSV-1 DNA and all patients with Ramsay Hunt syndrome tested positive for VZV DNA. With the absorption-based oral fluid collection system, detections rates and viral loads were found to be significantly lower when compared to those obtained with the liquid phase-based collection system. Collection of oral fluid with a liquid phase-based system and the use of automated and standardized molecular methods allow early and reliable detection of HSV-1 and VZV DNAs in patients with acute idiopathic peripheral facial nerve palsy and may provide a valuable decision support regarding start of antiviral treatment at the first clinical visit.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20648613     DOI: 10.1002/jmv.21849

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Reactivation of type 1 herpes simplex virus and varicella zoster virus in an immunosuppressed patient with acute peripheral facial weakness.

Authors:  Jean Tsai; Randall J Cohrs; Maria A Nagel; Ravi Mahalingam; D Scott Schmid; Alexander Choe; Don Gilden
Journal:  J Neurol Sci       Date:  2011-09-15       Impact factor: 3.181

2.  A cell culture model of facial palsy resulting from reactivation of latent herpes simplex type 1.

Authors:  Maggie A Kuhn; Shruti Nayak; Vladimir Camarena; Jimmy Gardner; Angus Wilson; Ian Mohr; Moses V Chao; Pamela C Roehm
Journal:  Otol Neurotol       Date:  2012-01       Impact factor: 2.311

Review 3.  Varicella-zoster.

Authors:  Don Gilden; Maria A Nagel; Randall J Cohrs
Journal:  Handb Clin Neurol       Date:  2014

Review 4.  Corticosteroids for Bell's palsy (idiopathic facial paralysis).

Authors:  Vishnu B Madhok; Ildiko Gagyor; Fergus Daly; Dhruvashree Somasundara; Michael Sullivan; Fiona Gammie; Frank Sullivan
Journal:  Cochrane Database Syst Rev       Date:  2016-07-18

5.  Antiviral treatment for Bell's palsy (idiopathic facial paralysis).

Authors:  Ildiko Gagyor; Vishnu B Madhok; Fergus Daly; Frank Sullivan
Journal:  Cochrane Database Syst Rev       Date:  2019-09-05

6.  Longitudinal Study of Hepatitis A Infection by Saliva Sampling: The Kinetics of HAV Markers in Saliva Revealed the Application of Saliva Tests for Hepatitis A Study.

Authors:  Luciane Almeida Amado Leon; Adilson José de Almeida; Vanessa Salete de Paula; Renata Santos Tourinho; Daniel Antunes Maciel Villela; Ana Maria Coimbra Gaspar; Lia Laura Lewis-Ximenez; Marcelo Alves Pinto
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

7.  Efficacy and Safety of Pharmacological and Physical Therapies for Bell's Palsy: A Bayesian Network Meta-Analysis.

Authors:  Jianwei Shi; Dafeng Lu; Hairong Chen; Mingzhu Shu; Yang Xu; Jiaojiao Qian; Ke Ouyang; Huaying Huang; Zhengxiang Luo; Chunhui Wang; Yansong Zhang
Journal:  Front Neurol       Date:  2022-04-18       Impact factor: 4.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.